Upgrade to SI Premium - Free Trial

Agenus (AGEN)

6.33 -0.18 (2.76%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Agenus to Provide Third Quarter 2026 Financial Report and Development Update October 22, 2026 4:30 PM - BizWire Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference October 9, 2026 3:23 PM - BizWire Armenia grants first-ever approvals for Agenus cancer drug combination October 8, 2026 7:31 AM - StreetInsider Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer October 8, 2026 7:30 AM - BizWire Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 October 3, 2026 10:50 AM - BizWire Form 4 AGENUS INC For: Oct 01 Filed by: Wright Timothy October 2, 2026 3:25 PM - SEC Filing Form 4 AGENUS INC For: Oct 01 Filed by: HARRISON THOMAS L October 2, 2026 3:22 PM - SEC Filing Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 October 2, 2026 9:00 AM - BizWire Rodman & Renshaw Starts Agenus Inc. (AGEN) at Buy September 28, 2026 7:02 AM - StreetInsider Chardan Starts Agenus Inc. (AGEN) at Buy September 18, 2026 5:02 AM - StreetInsider Form 4 AGENUS INC For: Aug 05 Filed by: Marcucci Marco Tullio September 16, 2026 2:41 PM - SEC Filing Form 3 AGENUS INC For: Aug 05 Filed by: Marcucci Marco Tullio September 15, 2026 4:56 PM - SEC Filing Form S-3 AGENUS INC September 11, 2026 4:46 PM - SEC Filing Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 September 10, 2026 7:30 AM - BizWire Agenus drug combo shows 33% three-year survival in colorectal cancer August 28, 2026 10:07 AM - StreetInsider Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism August 28, 2026 10:07 AM - BizWire Agenus reports no recurrences in Phase 2 colon cancer drug trial August 26, 2026 10:05 AM - StreetInsider Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer August 26, 2026 10:05 AM - BizWire Form 8-K AGENUS INC For: Aug 12 August 18, 2026 4:31 PM - SEC Filing Form EFFECT AGENUS INC August 17, 2026 6:17 AM - SEC Filing Form 424B3 AGENUS INC August 17, 2026 6:17 AM - SEC Filing Form 8-K AGENUS INC For: Aug 10 August 13, 2026 6:05 AM - SEC Filing Form 4 AGENUS INC For: Aug 10 Filed by: ARMEN GARO H August 12, 2026 9:30 PM - SEC Filing Form 8-K AGENUS INC For: Aug 05 August 11, 2026 4:30 PM - SEC Filing Form 4 AGENUS INC For: Aug 05 Filed by: HARRISON THOMAS L August 11, 2026 4:09 PM - SEC Filing Form 4 AGENUS INC For: Aug 05 Filed by: Corvese Brian August 11, 2026 4:07 PM - SEC Filing Agenus Inc. (AGEN) PT Lowered to $25 at H.C. Wainwright August 11, 2026 6:51 AM - StreetInsider Form 10-Q AGENUS INC For: Jun 30 August 7, 2026 4:32 PM - SEC Filing Form S-8 AGENUS INC August 7, 2026 4:17 PM - SEC Filing Form S-3 AGENUS INC August 7, 2026 4:03 PM - SEC Filing Form 4 AGENUS INC For: Aug 05 Filed by: Wright Timothy August 7, 2026 2:34 PM - SEC Filing Form 4 AGENUS INC For: Aug 05 Filed by: O'Day Steven J August 7, 2026 2:30 PM - SEC Filing Form 4 AGENUS INC For: Aug 05 Filed by: Hirsch Susan B August 7, 2026 2:17 PM - SEC Filing Form 4 AGENUS INC For: Aug 05 Filed by: Buell Jennifer August 7, 2026 2:08 PM - SEC Filing Form 8-K AGENUS INC For: Aug 06 August 6, 2026 7:53 AM - SEC Filing Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial August 6, 2026 7:30 AM - StreetInsider Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer August 6, 2026 7:30 AM - BizWire Agenus Inc. (AGEN) PT Raised to $14 at B.Riley July 30, 2026 8:47 AM - StreetInsider Agenus to Provide Second Quarter 2026 Financial Report and Development Update July 28, 2026 4:30 PM - BizWire Form EFFECT AGENUS INC July 28, 2026 6:05 AM - SEC Filing Form SCHEDULE 13G AGENUS INC Filed by: BlackRock, Inc. July 27, 2026 4:26 PM - SEC Filing Full Article List